Imperial College London
Portrait Picture

ProfessorHelenWard

Faculty of Medicine, School of Public Health

Professor of Public Health
 
 
 
//

Contact

 

+44 (0)20 7594 3303h.ward Website

 
 
//

Location

 

311School of Public HealthWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Scirica:2013:10.1056/NEJMoa1307684,
author = {Scirica, BM and Bhatt, DL and Braunwald, E and Steg, PG and Davidson, J and Hirshberg, B and Ohman, P and Frederich, R and Wiviott, SD and Hoffman, EB and Cavender, MA and Udell, JA and Desai, NR and Mosenzon, O and McGuire, DK and Ray, KK and Leiter, LA and Raz, I and SAVOR-TIMI, 53 Steering Committee and Investigators},
doi = {10.1056/NEJMoa1307684},
journal = {New England Journal of Medicine},
pages = {1317--1326},
title = {Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus},
url = {http://dx.doi.org/10.1056/NEJMoa1307684},
volume = {369},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart fa
AU  - Scirica,BM
AU  - Bhatt,DL
AU  - Braunwald,E
AU  - Steg,PG
AU  - Davidson,J
AU  - Hirshberg,B
AU  - Ohman,P
AU  - Frederich,R
AU  - Wiviott,SD
AU  - Hoffman,EB
AU  - Cavender,MA
AU  - Udell,JA
AU  - Desai,NR
AU  - Mosenzon,O
AU  - McGuire,DK
AU  - Ray,KK
AU  - Leiter,LA
AU  - Raz,I
AU  - SAVOR-TIMI,53 Steering Committee and Investigators
DO  - 10.1056/NEJMoa1307684
EP  - 1326
PY  - 2013///
SN  - 1533-4406
SP  - 1317
TI  - Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
T2  - New England Journal of Medicine
UR  - http://dx.doi.org/10.1056/NEJMoa1307684
UR  - http://hdl.handle.net/10044/1/40070
VL  - 369
ER  -
Download